Expert Interview
Discussing APG777 from Apogee Therapeutics in atopic dermatitis
Ticker(s): APGEInstitution: University of Rochester
- Professor of Dermatology, Professor of Medicine (AIR) and Pathology & Laboratory Medicine at University of Rochester Medical Center.
- Manages 500 patients with atopic dermatitis (60% Pediatric) and 30 patients per month with chronic urticaria.
- Research was instrumental in the development of dupilumab (Dupixent); Lead author of a 2014 NEJM paper that set the stage for the FDA approval of Dupixent.
Do you see your use of Dupixent in AD decreasing anytime soon?
Added By: wilson_adminWhat is the need for something like Dupixent with less frequent dosing?
Added By: wilson_adminHow optimistic are you for APG777?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
